BSECompany Update12 Sept 2026 · 12 Sept 2026, 04:52 pm
Intimation under Regulation 30 (LODR) -Raising of Funds
Aspira Pathlab & Diagnostics Ltd · 540788
✦ AI SummaryFundraise
Aspira Pathlab & Diagnostics Ltd has announced the outcome of its Board Meeting, where it has approved raising funds up to Rs. 65,00,00,000 through a Right Issue to eligible equity shareholders, subject to shareholder and regulatory approvals.
Analysis Scores
Earnings Impact5/10
Growth Catalyst4/10
Governance Concern1/10
Regulatory Risk3/10
Balance Sheet Risk2/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Raising of Funds
Attachments (1)
📄pdf
Download →
2e4482af-9d7f-42b3-b5c7-bc431332c0f3.pdf
View document text
Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand
Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction
LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209
Date: September 12, 2026
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.
Security Code: 540788
Security ID: ASPIRA
Sub: Outcome of Board Meeting
Ref: Outcome of Board Meeting held on September 12, 2026 under Regulation 30 of the SEBI (LODR)
Regulations, 2015
Dear Sir/Madam,
The Board of Directors of the Company in its meeting held on 12th September, 2026 have considered and
approved the following matters;
1) To raise Fund for an amount not exceeding Rs. 65,00,00,000/- (Rupees Sixty Five crores only), through
a Right Issue to the eligible equity shareholders of the Company as on Record date (to be notified
subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India
(Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, SEBI Listing Regulations,
along with relevant circulars issued by the Securities and Exchange Board of India, Companies Act, 2013
(“Right Issue”), subject to Shareholders & regulatory approval, if any. The rights issue will be either equity
or any other convertible instruments.
2) Constitute of the Right Issue Committee to proceed with the Right Issue and, inter-alia, decide the other
terms and conditions of the Right Issue, including deciding on the Record date, determining the rights issue
price, rights entitlement ratio, appointment of intermediaries and other related matters.
Name of the Composition Category
Committee
Right Issue Committee Mr. Nikunj Velji Mange Chairman
Mr. Vaibhav Odhekar Member
Mrs. Kiran Raghavendra awasthi Member
Mr. Balkrishna Subhash Talawadekar Member
The meeting commenced at 4.00 PM and concluded at 04.30 PM.
Kindly take the same on your record.
Thanking You.
Yours faithfully,
For Aspira Pathlab & Diagnostics Limited
Nikunj Velji Mange
Managing Director
DIN: 08489442
INDIA’S FIRST
0227197 5756, 022 2513 9090 www.aspiradiagnostics.com
FULLY INTEGRATED LAB support@aspiradiagnostics.com │info@aspiradiagnostics.com